8-K: Omeros' YARTEMLEA Gains FDA Nod for Fatal TA-TMA

Omeros Corporation announced FDA approval of YARTEMLEA (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Summary

• The U.S. Food and Drug Administration (FDA) has approved YARTEMLEA (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children ages two years and older.
• YARTEMLEA is the first and only approved therapy for TA-TMA, an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement.
• The approval was based on results from a pivotal trial (N=28 adults) showing a 61% complete response (CR) rate and an Expanded Access Program (EAP) (N=19 evaluable patients) showing a 68% CR rate.
• 100-day survival from TA-TMA diagnosis was 73% in the pivotal trial and 74% in evaluable EAP patients, with all patients meeting international harmonization criteria for high-risk TA-TMA.
• Omeros plans a U.S. product launch for YARTEMLEA in January 2026, with dedicated U.S. billing and reimbursement codes already in place.
• A marketing authorization application for YARTEMLEA for the treatment of TA-TMA is currently under review by the European Medicines Agency (EMA), with a decision expected in mid-2026.

Sentiment

Score: 9

Explanation: The FDA approval of a first-in-class therapy for a life-threatening condition with strong efficacy data is a highly positive event for the company and patients. The planned U.S. launch and ongoing EMA review further bolster positive sentiment, despite the noted adverse reactions which are common in this patient population.

Positives

• FDA approval of YARTEMLEA as the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
• High complete response (CR) rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP).
• Strong survival benefit demonstrated with 100-day survival rates of 73% in the pivotal trial and 74% in evaluable EAP patients.
• YARTEMLEA was associated with a threeto fourfold lower risk of mortality compared with an external control cohort.
• In previously refractory high-risk patients, YARTEMLEA achieved 50% one-year survival, significantly higher than historical rates of less than 20%.
• The approval includes an indication for children two years of age and older, addressing a critical unmet need in pediatric TA-TMA.
• YARTEMLEA has a favorable safety profile with no Boxed Warning and no Risk Evaluation and Mitigation Strategy (REMS), and vaccinations are not required prior to treatment.
• U.S. product launch is planned for January 2026, with dedicated billing and reimbursement codes already established.

Negatives

• Serious adverse reactions occurred in 61% of YARTEMLEA-treated patients, including acute kidney injury, confusional state, acute respiratory failure, neutropenic sepsis, septic shock, pulmonary edema, and vomiting.
• Fatal adverse reactions were reported in 7% of patients, including neutropenic sepsis and septic shock.
• Serious and life-threatening infections were reported in 36% of patients receiving YARTEMLEA in clinical trials.

Risks

• Unfavorable or unexpected regulatory conclusions or interpretations related to clinical data, external registry data, statistical analyses, or other information included in the YARTEMLEA MAA.
• Inability to respond satisfactorily to information requests during regulatory review of the YARTEMLEA MAA.
• Potential differences between the diagnostic criteria used in the pivotal trial and in the external registry, and whether the EMA determines the registry used in statistical analysis is sufficiently representative of TA-TMA patients.
• Unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions.
• Financial condition and results of operations, including the ability to raise additional capital for operations or complete other transactions on favorable terms or at all.
• Challenges associated with the manufacture or supply of products to support clinical trials, regulatory inspections, and/or commercial sale following any marketing approval.
• Changes in reimbursement and payment policies by government and commercial payers or the application of such policies.
• Intellectual property claims, competitive developments, and litigation.

Future Outlook

Omeros plans a U.S. launch of YARTEMLEA in January 2026, focusing on ensuring rapid and reliable access for patients. The company anticipates a decision from the European Medicines Agency (EMA) on YARTEMLEA's marketing authorization application by mid-2026. The pipeline also includes OMS1029, a long-acting MASP-2 inhibitor, OMS527 for cocaine use disorder, and a growing portfolio of oncology programs, with global rights to zaltenibart recently acquired by Novo Nordisk.

Management Comments

• "FDAs approval of YARTEMLEA marks a defining milestone for Omeros and, more importantly, for patients and families facing TA-TMA."
• "After years of work and close collaboration with the transplant community, we can now offer the first FDA-approved therapy for this frequently fatal complication, with robust response data and a benefit-risk profile that supports confident use in both adults and children."
• "With our U.S. launch planned for January 2026, our focus is on ensuring rapid, reliable access so that YARTEMLEA can be used when TA-TMA is recognized and time is critical."
• "We are deeply grateful to the patients, caregivers, investigators, and clinical teams who made this approval possible, and we are committed to bringing YARTEMLEA to every eligible patient who needs it."

Industry Context

The approval of YARTEMLEA addresses a significant unmet medical need in hematopoietic stem cell transplantation, as TA-TMA is an often-fatal complication with limited effective treatment options until now. The drug's mechanism as the first and only lectin pathway inhibitor for TA-TMA positions Omeros as a leader in this specific therapeutic area. The market for TA-TMA is substantial, with up to 56% of approximately 30,000 annual allogeneic transplant recipients in the U.S. and Europe potentially developing the condition. This approval sets a new standard of care, moving beyond reliance on supportive measures or off-label treatments.

Comparison to Industry Standards

• YARTEMLEA's 100-day survival rates of 73% (pivotal trial) and 74% (EAP) for high-risk TA-TMA patients significantly exceed historical outcomes, where mortality in severe TA-TMA can exceed 90%.
• Treatment with YARTEMLEA was associated with a threeto fourfold lower risk of mortality compared with an external control cohort (Matsui H, Arai Y, Kanda J, et al. Blood Adv. 2025).
• In previously refractory high-risk patients, YARTEMLEA achieved 50% one-year survival, compared with historical one-year survival rates reported as less than 20% (Schoettler ML, Pusarla SK, Nangia N, et al. Am J Hematol. 2025).
• For children refractory to one or more off-label complement inhibitors, YARTEMLEA's one-year survival is approximately triple historical rates that have remained below 20%.
• The drug's safety profile, without a Boxed Warning or REMS, is favorable compared to the risks associated with relying on off-label options or modifying calcineurin inhibitors, which can increase the risk of graft-versus-host disease.

Related Party Transactions

• Miguel-Angel Perales, M.D., Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center, has previously received advisory services compensation from, and holds a financial interest in, Omeros.
• Michelle Schoettler, M.D., Assistant Professor of Pediatric Oncology and Hematopoietic Cellular Therapy at Emory University, has previously received advisory services compensation from Omeros.

Stakeholder Impact

• **Shareholders**: Highly positive impact due to FDA approval of a first-in-class drug, opening a new market and revenue stream, and de-risking a significant part of the company's pipeline.
• **Patients (Adults and Children with TA-TMA)**: Significant positive impact by providing the first and only approved, effective treatment for an often-fatal complication, offering improved survival and response rates.
• **Healthcare Providers**: Provides a new, effective, and FDA-approved therapeutic option for a challenging condition, simplifying treatment decisions compared to reliance on supportive measures or off-label use.
• **Regulatory Authorities**: Successful outcome of a rigorous review process, validating the drug's safety and efficacy for a critical unmet need.
• **Employees**: Positive impact on morale and job security due to a major product approval and the initiation of commercialization efforts.

Next Steps

• U.S. product launch of YARTEMLEA in January 2026.
• Availability of the YARTEMLEAssist patient support program in Q1 2026.
• Conference call on January 7, 2026, to discuss the approval.
• Anticipated decision from the European Medicines Agency (EMA) on YARTEMLEA's marketing authorization application in mid-2026.

Key Dates

Recommendation

The FDA approval of YARTEMLEA as the first and only therapy for TA-TMA represents a monumental milestone for Omeros. This drug addresses a critical unmet medical need for a severe, often-fatal condition, with compelling efficacy data demonstrating high response rates and significantly improved survival compared to historical outcomes. The immediate market opportunity in the U.S., coupled with the ongoing EMA review for European market entry, positions YARTEMLEA for substantial commercial success. The established billing codes and patient support program indicate a well-prepared launch. While adverse reactions are noted, they are within the context of a critically ill patient population and do not diminish the drug's overall favorable benefit-risk profile. This approval de-risks a significant part of Omeros' pipeline and provides a strong foundation for future growth, making it a compelling 'strong buy' for investors.

Keywords

YARTEMLEA, narsoplimab-wuug, FDA approval, TA-TMA, hematopoietic stem cell transplant-associated thrombotic microangiopathy, Omeros Corporation, MASP-2 inhibitor, biotechnology, orphan drug, complement pathway